Amatuximab

Drug Profile

Amatuximab

Alternative Names: Anti-mesothelin monoclonal antibody; MORAb-009; MORAB-009-006

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Eisai Co Ltd; Morphotek
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Megakaryocyte potentiating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma
  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2015 Phase-II clinical trials in Mesothelioma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in Australia, France, Germany, Italy, United Kingdom after November 2015 (IV) (NCT02357147)
  • 01 Nov 2015 Phase-II clinical trials in Mesothelioma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (IV) (NCT02357147)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top